Steven P. Treon, M cognition-enhancing drugs .D., Ph.D, Christina K. Tripsas, M.A., Kirsten Meid, M.P.H., Diane Warren, B.S., Gaurav Varma, M.S.P.H., Rebecca Green, B.S., Kimon V. Argyropoulos, M.D., Guang Yang, Ph.D., Yang Cao, M.D., Lian Xu, M.S., Christopher J. Patterson, M.S., Scott Rodig, M.D., Ph.D., James L. Zehnder, M.D., Jon C. Aster, M.D., Ph.D., Nancy Lee Harris, M.D., Sandra Kanan, M.S., Irene Ghobrial, M.D., Jorge J. Castillo, M.D., Jacob P. Laubach, M.D., Zachary R. Hunter, Ph.D., Zeena Salman, B.A., Jianling Li, M.S., Mei Cheng, Ph.D., Fong Clow, Sc.D., Thorsten Graef, M.D., M.
During study termination, the principal final result had occurred in 80 percent of sufferers receiving dipyridamole plus aspirin and 84 percent of those getting placebo. Thrombosis was the most common overall trigger of the principal outcome, occurring in 40 percent of patients getting dipyridamole plus aspirin and in 42 percent of those receiving placebo. Angiography was performed in 59 percent of most sufferers with thrombosis, and stenosis of 50 percent or more was discovered in a lot more than 90 percent of these patients.72; 95 percent CI, 0.57 to 0.90; P=0.005). The median duration of cumulative graft patency was 22.5 months in the placebo group.